The average one-year price target for Terumo (OTCPK:TRUMF) has been revised to $19.81 / share. This is a decrease of 15.25% from the prior estimate of $23.38 dated November 16, 2025. The price target ...

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional ...

The average one-year price target for Terumo (OTCPK:TRUMF) has been revised to $23.38 / share. This is an increase of 14.97% from the prior estimate of $20.33 dated November 9, 2025. The price target ...

Terumo Corp. SEC filings breakout by MarketWatch. View the TRUMF U.S. Securities and Exchange Commission reporting information.

Terumo Corp (TRUMF) achieved record high sales revenues surpassing JPY1 trillion for the first time, with a 12% growth over the previous year. Operating profit reached a record high for the fourth ...

Terumo Corp (TRUMF) achieved all-time highs in revenue, operating income, and adjusted operating income for the third quarter. Revenue growth was 13% compared to the previous year, driven by strong ...

[Call Starts Abruptly] Thank you for your kind introduction. I’m Hagimoto, Terumo’s CFO. This presentation provides an overview of Terumo’s financial results for the third quarter of the fiscal year ...

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

) has been revised to $19.81 / share. This is a decrease of 15.25% from the prior estimate of $23.38 dated November 16, 2025. The price target is an average of many targets provided by analysts. The ...

Terumo Corp. Annual cash flow by MarketWatch. View TRUMF net cash flow, operating cash flow, operating expenses and cash dividends.